纤维蛋白原β(FGB)多克隆抗体

Polyclonal Antibody to Fibrinogen Beta Chain (FGB)

FG-B; Fibrinopeptide B; Fibrinogen Beta

  • 纤维蛋白原β(FGB)多克隆抗体 产品包装(模拟)
  • 纤维蛋白原β(FGB)多克隆抗体 产品包装(模拟)
  • PAB215Bo01.jpg Figure. Western Blot; Sample: Recombinant FGb, Cattle.
  • 纤维蛋白原β(FGB)多克隆抗体 Western Blot; Sample: Bovine Serum;
    Primary Ab: 1µg/ml Rabbit Anti-Bovine FGb Antibody
    Second Ab: 0.2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • 纤维蛋白原β(FGB)多克隆抗体 Western Blot; Sample: Bovine Liver lysate;
    Primary Ab: 1µg/ml Rabbit Anti-Bovine FGb Antibody
    Second Ab: 0.2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • 纤维蛋白原β(FGB)多克隆抗体 Western Blot; Sample: Bovine Spleen lysate;
    Primary Ab: 1µg/ml Rabbit Anti-Bovine FGb Antibody
    Second Ab: 0.2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • 纤维蛋白原β(FGB)多克隆抗体 Western Blot; Sample: Rat Liver lysate;
    Primary Ab: 1µg/ml Rabbit Anti-Bovine FGb Antibody
    Second Ab: 0.2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

特异性

该抗体是针对FGB的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别FGB。

用法

Western blotting: 0.5-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.

储存

经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。

赠品

相关产品

编号 适用物种:Bos taurus; Bovine (Cattle,牛) 应用(仅供研究使用,不用于临床诊断!)
RPB215Bo01 纤维蛋白原β(FGB)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAB215Bo01 纤维蛋白原β(FGB)多克隆抗体 WB; IHC; ICC; IP.
LAB215Bo71 纤维蛋白原β(FGB)多克隆抗体(生物素标记) WB; IHC; ICC.

参考文献

杂志 参考文献
United States Patent Application Compositions and Methods for Diagnosing Lung Cancer [y2016:0077095.html]
Microbial Pathogenesis Crystal structure of GAPDH of Streptococcus agalactiae and characterization of its interaction with extracellular matrix molecules [Pubmed: 30553015]
GLYCOCONJUGATE JOURNAL Nattokinase-heparin exhibits beneficial efficacy and safety—an optimal strategy for CKD patients on hemodialysis [Pubmed: 30788657]
留言咨询